Association of the Comprehensive End-Stage Renal Disease Care Model With Medicare Payments and Quality of Care for Beneficiaries With End-Stage Renal Disease

被引:25
|
作者
Marrufo, Grecia [1 ]
Colligan, Erin Murphy [2 ]
Negrusa, Brighita [1 ]
Ullman, Darin [1 ]
Messana, Joe [3 ]
Shah, Anand [4 ]
Duvall, Tom [4 ]
Hirth, Richard A. [4 ]
机构
[1] Lewin Grp, 3160 Fairview Pk Dr,Ste 600, Falls Church, VA 22042 USA
[2] Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA
[3] Univ Michigan, Kidney Epidemiol & Cost Ctr, Ann Arbor, MI 48109 USA
[4] Ctr Medicare & Medicaid Serv, Baltimore, MD USA
关键词
MORTALITY;
D O I
10.1001/jamainternmed.2020.0562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Question What is the association between Medicare's Comprehensive End-Stage Renal Disease Care model with Medicare payments and quality of care for beneficiaries with end-stage renal disease? Findings This economic evaluation including 133558 Medicare patients with end-stage renal disease found that, in its first 2 performance years, the Comprehensive End-Stage Renal Disease Care model was associated with lowered Medicare payments to providers and improved performance health care use and quality-of-care measures. Lower payments were primarily associated with reduced numbers of hospitalizations and readmissions; however, Medicare experienced net losses when shared savings payments were taken into account. Meaning Improved care coordination for Medicare beneficiaries with end-stage renal disease and better adherence to dialysis may reduce cost and improve quality. This economic evaluation assesses the association of the Comprehensive End-Stage Renal Disease Care model with Medicare payments, health care use, and quality of care. Importance Medicare beneficiaries with end-stage renal disease (ESRD) are a medically complex group accounting for less than 1% of the Medicare population but more than 7% of Medicare fee-for-service payments. Objective To evaluate the association of the Comprehensive End-Stage Renal Disease Care (CEC) model with Medicare payments, health care use, and quality of care. Design, Setting, and Participants In this economic evaluation, a difference-in-differences design estimated the change in outcomes for 73094 Medicare fee-for-service beneficiaries aligned to CEC dialysis facilities between the baseline (from January 2014 to March 2015) and intervention periods (from October 2015 to December 2017) relative to 60464 beneficiaries at matched dialysis facilities. In the CEC model, dialysis facilities, nephrologists, and other providers partner to form ESRD Seamless Care Organizations (ESCOs), specialty-oriented accountable care organizations that coordinate care for beneficiaries with ESRD. ESCOs with expenditures below a benchmark set by the Centers for Medicare & Medicaid Services are eligible to share in savings if they meet quality thresholds. A total of 685 dialysis facilities affiliated with 37 ESCOs participated in the CEC model as of January 2017. Thirteen ESCOs joined the CEC model on October 1, 2015 (wave 1), and 24 ESCOs joined on January 1, 2017 (wave 2). Patients with ESRD who were aligned with CEC dialysis facilities were compared with patients at matched dialysis facilities. Main Outcomes and Measures Medicare total and service-specific payments per beneficiary per month; hospitalizations, readmissions, and emergency department visits; and select quality measures. Results Relative to the comparison group (n = 60464; 55% men; mean [SD] age, 63.5 [14.4] years), total Medicare payments for CEC beneficiaries (n = 73094; 56% men; mean [SD] age, 63.0 [14.4] years) decreased by $114 in payments per beneficiary per month (95% CI, -$202 to -$26; P = .01), associated primarily with decreases in payments for hospitalizations and readmissions. Payment reductions were offset by shared savings payments to ESCOs, resulting in net losses of $78 in payments per beneficiary per month (95% CI, -$8 to $164; P = .07). Relative to the comparison group, CEC beneficiaries had 5.01 fewer hospitalizations per 1000 beneficiaries per month (95% CI, -8.45 to -1.56; P = .004), as well as fewer catheter placements (CEC beneficiaries with catheter as vascular access for periods longer than 90 days decreased by 0.78 percentage points [95% CI, -1.36 to -0.19; P = .01]) and fewer hospitalizations for ESRD complications (CEC beneficiaries were 0.11 percentage points less likely [95% CI, -0.20 to -0.02; P = .01] to be hospitalized in a given month). Total dialysis sessions and payments increased, suggesting improved adherence to dialysis treatments. Conclusions and Relevance Early findings from the CEC model demonstrate that a specialty accountable care organization model focused on a particular population was associated with reduced payments and improved quality of care. Future research can assess the longer-term outcomes of the CEC model and its applicability to populations with other complex chronic conditions.
引用
收藏
页码:852 / 860
页数:9
相关论文
共 50 条
  • [31] SPECT in End-Stage Renal Disease
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (09) : 26N - 27N
  • [32] Thrombosis in end-stage renal disease
    Casserly, LF
    Dember, LM
    SEMINARS IN DIALYSIS, 2003, 16 (03) : 245 - 256
  • [33] Lipids in end-stage renal disease
    Wanner, C
    JOURNAL OF NEPHROLOGY, 2002, 15 (02) : 202 - 204
  • [34] Osteoporosis in end-stage renal disease
    Lindberg, JS
    Moe, SM
    SEMINARS IN NEPHROLOGY, 1999, 19 (02) : 115 - 122
  • [35] Adiponectin and end-stage renal disease
    Markaki, Anastasia
    Psylinakis, Emmanuel
    Spyridaki, Aspasia
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2016, 15 (03): : 345 - 354
  • [36] Keloids and end-stage renal disease
    Freedman, BI
    Morrow, MA
    Tuttle, AB
    Igwemezie, BM
    Rich, SS
    Sherertz, EF
    Tuttlea, FNAJANAEB
    NEPHRON, 1998, 80 (02): : 244 - 246
  • [37] Hypertension in end-stage renal disease
    Martínez-Maldonado, M
    KIDNEY INTERNATIONAL, 1998, 54 : S67 - S72
  • [38] How end-stage renal disease (ESRD)-medicare developed
    Schreiner, GE
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (04) : S37 - S44
  • [39] End-Stage Renal Disease and Pregnancy
    Nadeau-Fredette, Annie-Claire
    Hladunewich, Michelle
    Hui, Dini
    Keunen, Johannes
    Chan, Christopher T.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2013, 20 (03) : 246 - 252
  • [40] Pregnancy and End-Stage Renal Disease
    Tangren, Jessica
    Nadel, Molly
    Hladunewich, Michelle A.
    BLOOD PURIFICATION, 2018, 45 (1-3) : 194 - 200